MedNet Solutions Announces Latest Release of its iMedNet EDC eClinical Solution
Significant Enhancements Demonstrate MedNet's Commitment to Efficiency and Ease-of-Use
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that the latest version of iMedNet™ EDC has been released to the iMedNet user community. iMedNet EDC provides an exceptionally flexible, intuitive and affordable cloud-based eClinical platform ideally suited to Sponsors and CROs wanting to quickly and easily build their own studies.
Release highlights include:
- CRF Dashboard – A novel new query management tool providing streamlined access to all queries, query histories, data field changes and approval histories…all from within the case report form (CRF) record.
- Auto Query – An extremely efficient mechanism to automatically apply and remove queries, and manually intervene when necessary.
- UAT Environment – Greatly simplifies user acceptance testing (UAT) prior to initial study release and mid-study updates.
- Productivity Enhancements – Numerous updates have been implemented throughout iMedNet…from Casebook Manager to Datasets on Demand…further augmenting clinical research efficacy.
“This latest release clearly demonstrates MedNet’s ongoing commitment to streamlining the clinical research process,” stated Tony Brown, iMedNet Product Manager at MedNet Solutions. “We’ll continue to refine and improve iMedNet over time to ensure it’s the best eClinical solution available anywhere. We’ll never rest on our laurels.”
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
